Introduction
Autologous hematopoietic stem cell transplantation is increasingly performed for the treatment of various pediatric and adolescent cancers, 1, 2 and currently most centers use peripheral blood stem cells (PBSC) as the source of stem cells to support high-dose chemotherapy. The advantages of PBSC include rapid hematopoietic recovery following transplantation, and less of a potential for tumor cell contamination of the grafts. 3 The dose of PBSC administered determines the success of engraftment, 4 which makes effective PBSC mobilization a critical step for the entire procedure. Methods for PBSC mobilization that are available for cancer patients include chemotherapy-induced mobilization, and mobilization by hematopoietic growth factor with or without chemotherapy. [5] [6] [7] [8] Although chemotherapy plus granulocyte colony-stimulating factor (G-CSF) is a standard mobilization regimen for patients with cancer, 9 there is great variability in predicting the optimal day to start collecting PBSC. In particular, it takes longer to reach the peak of circulating CD34 þ cells following pre-mobilization chemotherapy, especially in heavily pre-treated patients. Although the daily measurement of blood CD34 þ cells from the day of rising WBC to the day of apheresis has been used to determine the time to start collection, 10 the frequent measurement of CD34 þ cells is both time consuming and labor intensive. We sometimes miss the opportunity for collection when WBC is rising very slowly. Furthermore, owing to a paucity of technical staff, we seek to avoid collection procedures on weekends. These considerations motivated us to adopt mobilization with G-CSF alone for patients undergoing autologous transplantation. Mobilization with G-CSF alone is exclusively used for healthy donors, and the mobilization kinetics have been well studied. 11 Whether or not mobilization with chemotherapy plus G-CSF is preferable to mobilization with G-CSF alone remains to be established in the autologous setting. Mobilization with G-CSF alone in cancer patients might have advantages, such as ease of making a collection schedule without a daily determination of CD34 þ cells in the blood, and the avoidance of neutropenic fever and additional transfusion. In addition, mobilization with G-CSF alone can be performed on an outpatient basis. In this study, we examined the effectiveness of PBSC mobilization with G-CSF alone in pediatric and adolescent patients with solid tumors, including heavily treated patients.
Materials and methods

Patients
Data from 74 patients who were 21 years of age or younger and who underwent autologous PBSC harvest for primary cancer treatment between April 1997 and June 2005 were analyzed retrospectively. Their characteristics are shown in Table 1 . The patients, who were mobilized with G-CSF alone (N ¼ 56), were categorized according to prior treatment: patients who received four or fewer cycles of chemotherapy with/without local irradiation (Group 1; N ¼ 21); patients who received more than four cycles of chemotherapy, or three or more cycles of chemotherapy with extended irradiation such as cerebrospinal irradiation (Group 2; N ¼ 23); and patients who have been mobilized previously and received high-dose chemotherapy with PBSC support following conventional chemotherapy, and then they had a recurrent disease, and mobilization was attempted again (Group 3; N ¼ 12). In Group 3, the median time from the last high-dose chemotherapy to PBSC harvest was 8.5 months (range: 3-48). Patients who were mobilized with chemotherapy followed by G-CSF (N ¼ 18) during the same period in our institute were also evaluated as a control group. Groups 1-3, and the control group were comparable in age. The clinical protocols for peripheral blood stem cell transplantation (PBSCT) were approved by the Institutional Review Board at Tokushima University Hospital. Written informed consent was obtained from the patients (if the patient was more than 10 years old) or their guardians.
Peripheral blood stem cell mobilization and harvest For mobilization with G-CSF alone, G-CSF was initiated during the steady state, when blood cells had recovered from the influence of chemotherapy. The time from the last day of chemotherapy to the commencement of G-CSF averaged 19 days (range: 0-35; 0 means that patients did not receive chemotherapy before mobilization) in Group 1, 19 days (11-41) in Group 2 and 29 days in Group 3 (Table 1 ). Granulocyte colony-stimulating factor (10 mg/kg) was administered for 5 consecutive days. Principally, G-CSF was injected subcutaneously once a day at 0900 each day. Blood samples for daily analysis of complete blood count, colony-forming unit-granulocyte/macrophage (CFU-GM) assay and CD34 þ cell assay were drawn immediately before the injection of G-CSF. On day 5 of G-CSF treatment, after the fifth injection of G-CSF, PBSC harvest was commenced using a continuous cell separator.
For mobilization with chemotherapy plus G-CSF, the patients received disease-oriented chemotherapy; G-CSF was started when WBC reached a nadir, and complete blood counts were followed. The dose of G-CSF was 5 mg/kg intravenously, and was continued daily until the completion of PBSC harvest. We usually started to harvest PBSC when the platelet count reached over 100 Â 10 Apheresis was usually initiated at 1000 and 150-300 ml/kg (max. 10 l) was processed per session. The details of the harvesting procedure have been described previously. 12 Briefly, mostly in children less than 10 years old, blood was drawn from a radial artery using a 20-24 gauge catheter and given back to an antecubital vein using an 18-24 gauge catheter. For donors weighing less than 20 kg, the extracorporeal circuit was pre-primed with donated WBCdepleted blood, depending on the machine and separating chambers. In adolescents, we used antecubital veins to collect PBSC. Calcium gluconate was continuously infused at a dose of 1 ml per processed 200 ml blood during apheresis. The target doses were set at 42 Â 10 6 /kg CD34 þ cells for one course of high-dose therapy. In 19 of 56 patients who were mobilized with G-CSF alone, double PBSCT was planned, along with repeated aphereses to support two rounds of high-dose chemotherapy. Two aphereses were performed on day 5 in most patients, and additional aphereses were performed on days 6 and 7. Peripheral blood stem cells were cryopreserved in 10% dimethylsulfoxide in a deep freezer (À1501C) until use.
Mobilization failure was defined as a patient who never reached a CD34 þ cell level in the blood of 20 Â 10 6 /l, or a patient from whom a proper CD34 þ cell level was not collected in the first apheresis product, and in such cases we did not attempt further apheresis.
Flow cytometer analysis for CD34 þ cells
One hundred microliters of cell suspension were added to a test tube containing isotype control (phycoerythrin-mouse IgG1) and phycoerythrin-conjugated CD34 monoclonal antibody (anti-HPCA2 antibody; Becton Dickinson, San Jose, CA, USA) at a concentration of 1 mg antibody/10 6 cells. MNCs from samples were incubated for 30 min, and then washed twice. Samples were analyzed with a FACScan flow cytometer (Becton Dickinson). After the function was verified, samples were drawn into the flow cytometer using forward scatter and side scatter, as gating parameters, along with debris subtraction techniques to determine the characteristics of the cells. A total of 20 000 events were counted to identify the mononuclear cell fraction. The flow cytometric data were analyzed using a gated analysis via a set of SSC-FL parameters for CD34 þ cells to calculate the percentage of positive cells.
The number of circulating CD34 þ cells was calculated using the following formula:
Âpercentage of MNC ð%=100Þ Âfrequency of positive cells ð%=100Þ
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Statistical analysis
Statistical analysis was performed using SPSS statistical software (SPSS Co., Tokyo, Japan). Groups were compared using the non-paired t-test. The relationships between different hematological parameters and PBSC yields were analyzed by the Spearman rank correlation test. Pearson's sample correlation coefficient and the corresponding P-value were calculated for the null hypothesis of no correlation.
Results
Circulating cell kinetics during mobilization with granulocyte colony-stimulating factor alone ( Figure 1 PBSC mobilization by G-CSF alone in pediatric cancer patients H Watanabe et al tory CD34 þ cells and CFU-GM during mobilization were synchronized, and both of the peak values occurred on days 4 through 6 of G-CSF treatment. The numbers of CD34 þ cells and CFU-GM gradually increased between days 1 and 3, and markedly increased on days 4 and 6 following the initiation of G-CSF treatment. The peak CD34 þ cell level was observed on day 5 in 37 of 56 patients (66%), on day 4 in 10 patients (18%) and on day 6 in nine patients (16%). The peak CFU-GM level was observed on day 5 in 40 of 56 patients (71%), on day 4 in seven patients (13%) and on day 6 in nine patients (16%). The median numbers of circulating CD34 þ cells and CFU-GM on day 5 were 62.4 Â 10 6 /l (4.13-192.60) and 11.16 Â 10 6 /l (0.056-48.98), respectively.
Mobilization effects and peripheral blood stem cell apheresis yields
The results of mobilization and apheresis are shown in Table 2 . Peripheral blood stem cell yields were calculated as number per unit of processed blood (l) per unit weight of the patient (kg). The peak values of circulating CD34 þ cells and CFU-GM in Group 3 were significantly lower than those in Groups 1 (P ¼ 0.002) and 2 (P ¼ 0.049). Compared to patients mobilized by chemotherapy plus G-CSF, the CD34 þ cell yields were significantly lower in all of the patients mobilized with G-CSF alone (P ¼ 0.045). Compared to patients mobilized by chemotherapy plus G-CSF, the CD34 þ cell yields were significantly lower in Group 3 patients (P ¼ 0.014). Compared to patients mobilized by chemotherapy plus G-CSF, the CFU-GM yields were significantly lower in Group 2 (P ¼ 0.033). The CD34 þ cell yield was significantly lower in Group 3 compared to Group 1 (P ¼ 0.014). There were no differences in CD34 þ cell yields between Groups 1 and 2, and the control group. The CFU-GM yield in Group 1 was significantly higher than that in Groups 2 and 3 (P ¼ 0.033 and 0.048, respectively).
We analyzed several factors that might be used to predict PBSC yields such as age and hematological parameters before and during G-CSF treatment in all of the patients who were mobilized with G-CSF alone. In all of these patients, the number of circulating CD34 þ cells on day 5 was significantly correlated with the CD34 þ yield (Figure 2 ). There was no significant correlation between any other factors and PBSC yields.
Toxicity of the mobilization procedure
No patient required a reduced dose of G-CSF. The adverse effects induced by G-CSF injection were tolerable in all groups. Although patients mobilized with G-CSF alone who were older than 10 years sometimes complained of slight fever, bone pain, lumbago or mild headache, this was sustained with or without medication. Clinical signs of severe infection were not evident in patients mobilized with G-CSF alone. However, among patients mobilized with chemotherapy plus G-CSF, almost all of the patients experienced neutropenia, and the nadir ANC was 0.1-0.4 Â 10 9 /l. There were episodes of fever during neutropenia Table 2 Mobilization and collection of PBSC by apheresis Abbreviations: CFU-GM ¼ colony-forming units-granulocyte/macrophage; G-CSF ¼ granulocyte colony-stimulating factor; PBSC ¼ peripheral blood stem cells. PBSC were collected to support double sequential high-dose chemotherapy in three patients in Group 1, 12 patients in Group 2, four patients in Group 3 and no patients in the control group. Number was divided by the target number of planned high-dose chemotherapies. *Significantly low compared to the control group. in 13 of 18 patients (72%) mobilized with chemotherapy plus G-CSF, which required treatment with intravenous antibiotics and/or antifungal agents. Culture was positive for five patients who were mobilized with chemotherapy plus G-CSF.
Engraftment
The results of engraftment following autologous PBSCT are shown in Table 3 . In Group 1, high-dose chemotherapy was cancelled because of progressive disease in one. In Group 2, high-dose chemotherapy was cancelled because of stable disease in one and poor PBSC collection in one. In Group 3, only one patient declined high-dose chemotherapy because of poor PBSC collection, and proceeded to allogeneic cord blood cell transplantation. Three patients in Group 1, 12 in Group 2 and four in Group 3 received double sequential high-dose chemotherapy. None of the patients in the control group received double transplantation. There were no significant differences in WBC and ANC engraftment among all groups, although platelet recovery was delayed in patients mobilized with G-CSF alone, especially Group 3 patients. Graft failure was not observed in any of the transplanted patients.
Discussion
This study was a retrospective analysis of pediatric and adolescent patients with solid tumors treated with autologous PBSCT at our institution. Therefore, the disease and conditioning regimens are heterogeneous. In addition, the relatively small number of patients in some treatment groups and the retrospective analysis may make it difficult to draw any definitive conclusions. Nevertheless, our data suggest that G-CSF alone may be capable of mobilizing a sufficient number of PBSC for successful autografting after high-dose chemotherapy in pediatric and adolescent patients with solid tumors. The study of mobilization kinetics showed a similar pattern of PBSC mobilization with allogeneic donors, and the peaks of circulating CD34 þ cells and CFU-GM were observed on days 4 through 6 of G-CSF treatment. Thus, when PBSC are mobilized by G-CSF alone, we can easily determine the þ cell yields were calculated as number per unit of processed blood (l) per unit weight of the patient (kg). Table 3 Engraftment results timing of commencing PBSC harvest without monitoring the daily CD34 þ cell concentration. In contrast, in mobilization with chemotherapy plus G-CSF, it might be difficult to determine the optimal timing of PBSC harvest following chemotherapy because of the wide range of optimal mobilization time points. 9 In mobilization with chemotherapy plus G-CSF, suggested predictive factors for initiating harvests have included the peripheral WBC count, circulating CD34 þ cells, the peripheral absolute monocyte count and the platelet count. 10, 13 The measurement of CD34 þ cells in peripheral blood before PBSC harvest has begun to be used, but it is too labor intensive to determine this value every day around the time of PBSC harvest. Furthermore, when chemotherapy is used for PBSC mobilization, myelosuppression induced by chemotherapy is inevitable, and we might repeat unwanted chemotherapy simply to mobilize PBSC, and thus cause additional costs for patient care. Most patients who received chemotherapy for PBSC mobilization required treatment of neutropenic fever, 14 as in our study. Drawbacks for mobilization with G-CSF alone include a 1-week delay of scheduled chemotherapy and a lack of antitumor effects. However, if we started to harvest after two or three courses of chemotherapy instead of in the early phase of chemotherapy, this delay might not affect the outcome of the disease. Although the dose of G-CSF is higher in mobilization with G-CSF alone than in post-chemotherapy mobilization, the duration of G-CSF administration can be much longer in postchemotherapy administration than in mobilization with G-CSF alone. The total dose of G-CSF in post-chemotherapy mobilization might be greater than in mobilization with G-CSF alone. Thus, mobilization with G-CSF alone might offer clinical and economic advantages, and might increase convenience and improve the QOL of patients.
It is often difficult to obtain the minimum requirement of CD34 þ cells for safe engraftment after autologous PBSCT in heavily pre-treated patients. In adult lymphoma patients, predictors of poor mobilization were more than two prior treatment regimens and the WBC count on the first day of apheresis. 15, 16 In another study, patients who failed to mobilize had received more than seven cycles, and the authors advocated that PBSC collection should be planned early in the course of chemotherapy. 17 In adult cancer patients, factors that predict a higher likelihood of poor mobilization include increasing numbers of cycles of prior chemotherapy, prior radiation therapy and the presence of overt marrow metastasis. [18] [19] [20] Autologous donors are assumed to have sustained an injury to the hematopoietic stem cell system that is responsible for the poor mobilization. Limited data are available with regard to PBSC collection with G-CSF alone in pediatric patients with cancer. 21 We showed that PBSC could be mobilized by G-CSF alone even in most of the heavily treated pediatric patients with solid tumors using the same dose as in healthy donors. Most of the patients received platinum-based or alkylator-based chemotherapy before PBSC harvest. We could not analyze the effects of specific chemotherapeutic agents on PBSC mobilization. We merely analyzed the effects of the degree of previous chemotherapy on PBSC mobilization. Obviously, when the patients were categorized according to prior treatment, the frequency of poor mobilization depended on the degree of previous treatment. In our study, we stopped collecting PBSC in four patients. A previous study showed that the frequency of poor mobilizers was 14% in patients mobilized with G-CSF alone, 14 which was similar to our experience. The doseescalation effects of G-CSF alone or in combination with other cytokines in such patients should be investigated to improve the efficacy of PBSC mobilization.
Peripheral blood stem cell yields might be lower in the G-CSF alone group than in the chemotherapy plus G-CSF mobilization group. However, there is no difference in the number of aphereses between the G-CSF alone group and the chemotherapy plus G-CSF group. A threshold level of infused progenitors might exist for successful PBSCT. Most pediatric and adolescent patients with solid tumors who are candidates for high-dose chemotherapy with autologous PBSC support mobilize enough PBSC to ensure the collection of a PBSC product that is capable of rapid hematological recovery, when mobilization is attempted with G-CSF alone or in combination with chemotherapy. Mobilization with G-CSF alone is capable of collecting PBSC over this threshold level, and there were no graft failures, even in heavily pre-treated patients.
In conclusion, mobilization with G-CSF alone was effective even in pediatric and adolescent patients with solid tumors who received more than three cycles of chemotherapy or with extensive irradiation, although platelet recovery following autologous PBSCT was delayed. Mobilization with G-CSF alone in cancer patients might offer some advantages, such as ease of determining a collection schedule without a daily determination of CD34 þ cells in the blood, and the avoidance of neutropenic fever and additional transfusion.
